Skip to content
Search

Latest Stories

NHS approves pill to help prevent breast cancer

Around 289,000 women at moderate or high risk of breast cancer could be eligible for the drug

NHS approves pill to help prevent breast cancer

Thousands of women facing a higher risk of breast cancer are set to receive aid through a risk-reducing drug, now approved for use by the NHS. The state-funded health service made the announcement on Tuesday (7), marking a significant step in preventing the disease.

Anastrozole, a long-standing breast cancer treatment has been licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) as a preventive measure, raising hopes of averting numerous breast cancer cases in England.


The National Institute for Health and Care Excellence initially suggested Anastrozole as a preventive choice in 2017.

The off-patent drug (meaning more than one company can make it) demonstrated through trials, significantly reduces the disease's occurrence by nearly 50 per cent in post-menopausal women facing increased risks.

“Breast cancer is the most common cancer in the UK, so I'm delighted that another effective drug to help to prevent this cruel disease has now been approved,” said health minister Will Quince.

“We've already seen the positive effect Anastrozole can have in treating the disease when it has been detected in postmenopausal women and now, we can use it to stop it developing at all in some women. This is a great example of NHS England's innovative Medicines Repurposing Programme supporting the development of new ways for NHS patients to benefit from existing treatments,” he said.

Around 289,000 women at moderate or high risk of breast cancer could be eligible for the drug, and while not all will choose to take it, it is estimated that if 25 per cent do, around 2,000 cases of breast cancer could potentially be prevented in England, while saving the NHS around GBP 15 million in treatment costs.

“This is the first drug to be repurposed though a world-leading new programme to help us realise the full potential of existing medicines in new uses to save and improve more lives on the NHS. Thanks to this initiative, we hope that greater access to anastrozole could enable more women to take risk-reducing steps if they'd like to, helping them live without fear of breast cancer,” said NHS chief executive Amanda Pritchard.

The treatment is taken as a 1mg tablet, once a day for five years. Anastrozole is an aromatase inhibitor, which works by cutting down the amount of the hormone oestrogen that a patient's body makes by blocking an enzyme called “aromatase.”

The most common side effects of the medicine are hot flushes, feeling weak, pain/stiffness in the joints, arthritis, skin rash, nausea, headache, osteoporosis, and depression.

Anyone who suspects they are having a side effect from this medicine is encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA's Yellow Card scheme.

“The extension of anastrozole's licence to cover it being used as a risk-reducing treatment is a major step forward that will enable more eligible women with a significant family history of breast cancer, to reduce their chance of developing the disease,” said Baroness Delyth Morgan, chief executive at the Breast Cancer Now charity.

The UK's Medicines Repurposing Programme was set up in 2021 and is hosted by NHS and supported by the government to build on the innovation in medicines repurposing seen during the Covid-19 pandemic, when tocilizumab, an arthritis drug, and dexamethasone, a widely available steroid, was repurposed as treatments for coronavirus.

(With inputs from PTI)

More For You

The Sattva Collective launches to support South Asian women

The initiative will empower more women to speak openly about their health

iStock

The Sattva Collective launches to support South Asian women through midlife and menopause

A new community-led initiative has been launched in the UK to provide culturally sensitive support for South Asian women navigating midlife and menopause.

The Sattva Collective, founded by certified Midlife and Menopause Coach Kiran Singh, officially launched on 14 May 2025 as a registered Community Interest Company (CIC). It is the first initiative in the UK focused specifically on the experiences of South Asian women during what Singh describes as a “deeply personal and often stigmatised” phase of life.

Keep ReadingShow less
Bella Hadid

Bella Hadid stuns at the Cannes Film Festival 2025 in a daring Saint Laurent black gown

Instagram/ Vogue France

Bella Hadid pushes Cannes 2025 dress code to the edge in a daring Saint Laurent black gown

Bella Hadid’s return to the Cannes Film Festival was anything but quiet. This year, the model showed up ready to challenge the red carpet rules without actually breaking them.

With new restrictions in place like no sheer fabrics, no visible nudity, no dramatic trains or bulky silhouettes, fashion-watchers wondered if Bella, known for her daring Cannes looks in the past, would tone it down. Instead, she found a clever way around the rules.

Keep ReadingShow less
Gen Z

These terms provide insight into how Gen Z views the world around them

iStock

11 Gen Z slang terms that have already peaked in 2025

Language is constantly evolving, and nowhere is this more apparent than in the lexicon of Gen Z. As the first generation to grow up fully immersed in social media, their language is influenced by memes, viral videos, and digital culture. With 2025 underway, several Gen Z slang terms have already become ubiquitous, appearing in everyday conversations, on social media platforms, and even in mainstream media. Here are 11 slang terms that have already peaked this year.

1. Delulu

"Delulu," short for "delusional," is one of the most prominent slang terms of 2025. It’s used to describe someone who holds unrealistic beliefs or makes outlandish claims. The term was catapulted into the spotlight after Australian Prime Minister Anthony Albanese used it in Parliament to describe his political opponents, referring to them as being "delulu with no solulu," which translates to "delusional with no solution." The term has since been widely adopted by young people, particularly in online communities. It’s now frequently used to poke fun at someone’s exaggerated or disconnected views on social media.

Keep ReadingShow less
FDA Urges Immediate Stop to Use of Recalled Eye Care Products

The FDA has categorised the recall as a Class II

iStock

Eye care products recalled across US over sterility concerns, FDA warns users to stop immediately

A nationwide recall of five eye care products has been issued in the United States after concerns were raised about their sterility and manufacturing standards. BRS Analytical Services, LLC, the manufacturer of the affected products, has urged consumers to stop using them immediately due to potential safety risks.

The recall, shared in a press release by healthcare distributor AvKARE, affects more than 1.8 million cartons of eye drops. The US Food and Drug Administration (FDA) identified multiple violations during a recent audit, including failures to meet Current Good Manufacturing Practice (CGMP) standards.

Keep ReadingShow less
Zepbound Surpasses Wegovy in Groundbreaking Weight Loss Study

This may influence future decisions on treatment options for obesity patients

iStock

Eli Lilly's Zepbound outshines Wegovy in weight loss trial results

Eli Lilly announced on Sunday that its weight-loss drug, Zepbound, outperformed Novo Nordisk's Wegovy in a head-to-head trial, showing superior results across five weight-loss targets, including waist circumference reduction.

This trial, the first of its kind comparing the two widely used obesity medications, offers Eli Lilly a competitive advantage as it aims to secure broader insurance coverage in the rapidly growing obesity drug market, which is projected to exceed $150 billion annually by the next decade.

Keep ReadingShow less